Trial Profile
Anti-E1E2 Antibodies for the Prediction of Virological Response to Triple Therapy in Treatment-experienced Hepatitis C Virus-cirrhosis Cases
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Telaprevir (Primary) ; Peginterferon; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 14 Sep 2016 New trial record